vision Biointaxis
To defeat rare diseases and
restore patient's health


vision Biointaxis
We develop life-changing treatments for
rare genetic diseases such as Friedreich’s ataxia


vision Biointaxis
Patient - centric / Act, beyond hope
Business for good / Accountability / Team-up

Science : Involved & Commited

We develop a Gene therapy product to re-establish the function of a defective protein in Friedreich ataxia Patients.

Biointaxis creates significant value at the early stages of product development (R&D), Pre-clinical (proof-of-concept and regulatory) and early clinical trials (Phase I/II). We aim to license the production and distribution rights to Pharma partners equipped with a reputation. Biointaxis is an academic spin-off company benefiting from extensive know-how in the identification of genes and mechanisms underlying neurodegenerative disorders. As shown in the table below our the leading candidate is a gene therapy product for the treatment of Friedreich Ataxia.

Science : Involved & Commited



Biointaxis is an academic Biotech spin-off recently created from the Health Sciences Research Institute Germans Trias i Pujol (IGTP) located in Badalona, Barcelona.

The team is led by Dr. Matilla and Dr. Sánchez both pioneers in the identification of ataxia genes and research in neurodegenerative disorders.

We are currently developing a gene therapy treatment for Friedreich´s ataxia, a rare inherited, progressive, neurodegenerative disease that typically affects teenagers and young adults.  Our research shows efficacy of the treatment being able to re-establish the neurological functions in mice models of Friedreich´s ataxia.

We develop life-changing treatments for rare genetic diseases such as  Friedreich’s ataxia.

Management & Advisory Board

Biointaxis CEO
Antoni Matilla Dueñas Ph.D.
CEO & Co Founder
* Head of the Translational Functional Neurogenetics Unit of the Germans Trias i Pujol Research Institute (IGTP)
Biointaxis CEO
Ivelisse Sánchez Ph.D.
CSO & Co Founder
* Principal Investigator and co-Director Laboratory of Functional Biology and Experimental Therapies in Neurosciences (IGTP)
Biointaxis CEO
Jaime Melendo
Board Member & Co Founder
* 32 year expertise in Pharma and Biotech. CEO and shareholder of Gentec Pharmaceutical Group.
Biointaxis CEO
Daniel Pérez
Chief Financial Officer
* 11 years as Finance Director in Gentec Pharmaceutical Group.
Biointaxis CEO
Luis Ruiz Avila Ph.D.
Senior Business Advisor
* 17 years experience as CEO in Biotech.
Biointaxis CEO
Miguel Chillón Ph.D.
Scientific Advisor
* ICREA Professor with 23 years of experience in gene therapy strategies using AAV viral vectors in vivo models of human diseases

Biointaxis creates significant value at the early stages of product development, R&D, Pre-clinical (proof-of-concept and regulatory) and clinical trials (Phase I/II).


El Ministerio de Ciencia e Innovación, dentro del Programa Estatal de Investigación Científica y Técnica y de Innovación 2017-2020, concedió ayuda al proyecto "Desarrollo de un fármaco innovador de terapia génica para el tratamiento de la Ataxia de Friedreich" liderado por BIOINTAXIS S.L. con número de expediente RTC-2019-006995-1. Este proyecto ha sido financiado por el Ministerio de Ciencia e Innovación dentro del Subprograma RETOS-COLABORACIÓN, Convocatoria 2019.
EU Seal

Biointaxis ha sido beneficiaria de un Proyecto NEOTEC subvencionado por el CDTI con la colaboración del Ministerio de Economía, Industria y Competitividad (MINECO). Número de expediente SNEO-20191074

El Ministerio de Ciencia, Innovación y Universidades, dentro del Proyecto Estratégico para la Recuperación y Transformación Económica para la Salud de Vanguardia (PERTE de Salud), concedió ayuda al proyecto "FRATAXAV: Terapia Génica para la Ataxia de Friedreich" liderado por BIOINTAXIS S.L. con expediente EXP 00156531 / IDI-20230057, ejecutado bajo el Plan de Recuperación, Transformación y Resiliencia (PRTR). Este proyecto ha sido financiado con el Mecanismo de Recuperación y Resiliencia (MRR) de la Unión Europea – NextGenerationEU.